Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 1:38 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1441–1464 of 48,510 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: AS+ Clear all

Conditions: Urologic Diseases, Antibacterial Drug Adverse Reaction
Interventions: Audit-and-feedback; Behavioral
Lead sponsor: Iowa City Veterans Affairs Medical Center; Federal
Eligibility: Not listed
Enrollment: 525 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 3
States / cities: Gainesville, Florida • Iowa City, Iowa • New York, New York

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: hypertonic saline, standard saline; Drug
Lead sponsor: OhioHealth; Other
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Chlamydia, Gonorrhea
Interventions: Home screening, Clinic screening; Behavioral
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 14 Years to 45 Years · Female only
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Perinatal Anxiety, Perinatal Depression
Interventions: Patient Navigation (PN), Problem Solving Therapy (PST); Behavioral
Lead sponsor: American University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Smoking Cessation
Interventions: Smoking Cessation Behavioral Program, Nicotine Patch, Physical Activity; Behavioral · Drug
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 400 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2003
U.S. locations: 2
States / cities: Memphis, Tennessee

Conditions: Metabolic Syndrome, Obesity
Interventions: Exercise Intervention; Behavioral
Lead sponsor: Plymouth State University; Other
Eligibility: 18 Years to 39 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2024
U.S. locations: 2
States / cities: Plymouth, New Hampshire

Conditions: Cough, Parkinson's Disease
Interventions: Capsaicin, Voluntary cough test; Drug · Other
Lead sponsor: University of Florida; Other
Eligibility: 55 Years to 85 Years
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 2
States / cities: Gainesville, Florida

Conditions: Amputation Pain
Interventions: Strong But Comfortable TENS, Just Perceptible TENS; Device
Lead sponsor: University of Delaware; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Anxiety
Interventions: Acamprosate; Drug
Lead sponsor: State University of New York - Upstate Medical University; Other
Eligibility: 18 Years to 64 Years
Enrollment: 13 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Syracuse, New York

Conditions: Adherence, Patient
Interventions: Immulina; Drug
Lead sponsor: University of Mississippi Medical Center; Other
Eligibility: 18 Years to 50 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Jackson, Mississippi

Conditions: Childhood Obesity Prevention
Interventions: Boys and Girls Club summer day camp; Behavioral
Lead sponsor: The Miriam Hospital; Other
Eligibility: 6 Years to 12 Years
Enrollment: 94 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Asthma in Children, Atopy, Viral Upper Respiratory Infection
Interventions: Omalizumab, Placebo; Drug
Lead sponsor: Children's National Research Institute; Other
Eligibility: 6 Years to 17 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Hepatic Encephalopathy, Cirrhosis, Nonalcoholic Steatohepatitis, Hepatitis C
Interventions: Not listed
Lead sponsor: OSF Healthcare System; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Peoria, Illinois

Conditions: Stress Disorders, Post-Traumatic, Stress Disorders, Traumatic, Acute
Interventions: Neuropeptide Y, Placebo; Drug · Other
Lead sponsor: New York Medical College; Other
Eligibility: 18 Years to 65 Years
Enrollment: 117 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 2
States / cities: Valhalla, New York

Conditions: Non-Alcoholic Fatty Liver Disease
Interventions: Sigmoidoscopy; Procedure
Lead sponsor: AdventHealth Translational Research Institute; Other
Eligibility: 35 Years to 65 Years
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Migraine
Interventions: Saline, lidocaine/bupivacaine; Drug · Combination Product
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years to 80 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Anxiety, ESRD
Interventions: Survey; Other
Lead sponsor: The Rogosin Institute; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Sport-related Concussion
Interventions: Screen Time Restriction (ST-Restricted), Aerobic Exercise (AE), Screen-time restricted plus aerobic exercise (STR+AE), Stretching Only; Behavioral
Lead sponsor: Children's Health; Other
Eligibility: 12 Years to 17 Years
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Plano, Texas

Conditions: Pancreatic Adenocarcinoma
Interventions: Temsirolimus, Gemcitabine; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Metastatic Neuroendocrine Prostate Cancer
Interventions: [68Ga]Ga-PSMA-11, [68Ga]GA-DOTA-TATE, [68Ga]Ga-NeoB, [177Lu]Lu-PSMA-617, [177Lu]Lu-DOTA-TATE, [177Lu]Lu-NeoB, L-Lysine HCl-L-Arginine HCl, 2.5 %,, Gonadotropin-releasing hormone (GnRH) analogues, GnRH antagonists, Antiemetics & antinauseants, Metoclopramide; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years · Male only
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 2
States / cities: Omaha, Nebraska • New York, New York

Conditions: Healthy Subjects
Interventions: Ziresovir, Placebo; Drug · Other
Lead sponsor: Shanghai Ark Biopharmaceutical Co., Ltd.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Secaucus, New Jersey

Conditions: Chronic Myeloid Leukemia, Chronic Phase, Adult CML, Leukemia, Myeloid, Leukemia,Myeloid, Chronic
Interventions: Single Agent Asciminib, Low TKI, Elective Free Treatment; Drug · Combination Product · Other
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2032
U.S. locations: 8
States / cities: Birmingham, Alabama • Atlanta, Georgia • Augusta, Georgia + 5 more

Conditions: Pain
Interventions: Acupuncture; Other
Lead sponsor: Allina Health System; Other
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Polyneuropathies, Wild Type ATTR Amyloidosis, Wild-Type Transthyretin-Related (ATTR)Amyloidosis, Wild-Type Transthyretin Cardiac Amyloidosis, Transthyretin Amyloidosis
Interventions: patisiran; Drug
Lead sponsor: Austin Neuromuscular Center; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Austin, Texas

Search by objective public record fields.

Audit-and-feedback to Improve Antimicrobial-prescribing Among Urologists

Nebulized Hypertonic Saline for Inpatient Use in COPD

Randomized Trial of Home Versus Clinic-based Screening for Sexually Transmitted Infections

Improving Perinatal Mental Health Through a Collaborative, Community Health Worker and Social Worker Intervention

Increasing Physical Activity as Part of a Smoking Cessation Program

Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control

Respiratory Kinematics of Cough in Healthy Older Adults and Parkinson's Disease

Stimulation for Amputation Pain Management

An 8 Week Open-Label Study to Evaluate the Efficacy and Safety of Acamprosate Calcium (Campral) as Augmentation Therapy in Patients With Anxiety Symptoms Who Are Only Partial Responders to SSRI or SNRI Antidepressants

Identification of Surrogate Blood and/or Urine Biomarker for Immulina TM (Trademark) in Normal Humans

Testing the Feasibility and Preliminary Effect of Summer Camp

Omalizumab Before Onset of Exacerbations

Default Mode Network fMRI Maps as a Predictive Index of Hepatic Encephalopathy Outcome

Intranasal Neuropeptide Y in Clinical Trial in Level Two Trauma Patients for PTSD and Acute Stress Disorder

Microbiome-Mediated Gut Dysfunction in Non-Alcoholic Fatty Liver Disease

A Research Study of Greater Occipital Nerve Block as a Treatment for Acute Migraine Attacks

Anxiety and Symptom Burden in Hemodialysis Patients

Concussion Screen Use Recovery Time

Temsirolimus in Combination With Gemcitabine in Previously Untreated Metastatic Pancreatic Cancer

NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.

A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Ziresovir in Healthy Subjects

Asciminib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Chronic Phase

Acupuncture in the Emergency Department

Spectrum of Peripheral and Autonomic Neuropathies in Patients With aTTRwt Amyloidosis and Response to Patisiran Therapy